Q-omics provides the consensus-scored GAPDHP30 profile across patient tissues and cancer cell-line models. GAPDHP30 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, GAPDHP30 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, GAPDHP30 RNA expression shows 3,800 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, KIRC, and STAD as cancer lineages where GAPDHP30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP30 survival associations across molecular data types. GAPDHP30 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP30 RNA expression–survival associations across cancer types. High GAPDHP30 expression shows unfavorable associations in THCA, READ, CHOL, STAD and LIHC, but favorable associations in UCS. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for GAPDHP30 RNA expression.
This table summarizes GAPDHP30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP30 shows higher tumor expression in KIRC and LUSC. The KIRC box plot shows higher GAPDHP30 RNA expression in tumor versus normal tissue (log2 FC = +0.024, t-test p = .003).
This table shows molecular features associated with GAPDHP30 in patient tissues and cancer cell lines. In patient samples, GAPDHP30 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
